- Email: [email protected]
4894225 Combination therapy using antitumor immunotoxins with tumor necrosis factor
45~J
PATENT ABSTRACTS
have apparent molecular weights of 230K, 215K, 205K, and 190K respectively, with differences in their carbohydrate moieties, nAb 4C is a IgG sub two a, kappa immunoglobulin. 4C has potential use in leukemia, hematopoietic cell differentiation and transplantation diagnoses and therapy.
4892935 ANTI-HUMAN
PULMONARY
CARCINOMA MONOCLONAL ANTIBODY Hajime Yosbida, Nobuo Hanai, Kenya Shitara, Sagamihara, WA, Japan assigned to Kyowa Hakko Kogyo Co Ltd
4892933 MONOCLONAL ANTIBODY FOR COLORECTAL CARCINOMA Ronald Salem, Peter Thomas, Norma Zamcheck, Glenn Steele assigned to New England Deaconess Hospital Corporation; Mallory Institute of Pathology Foundati A monoclonal antibody raised to colorectal carcinoma, and a hybridoma which elicits the antibody, have been produced. This antibody, ND4 has been discovered to react with a new tumor marker, a glycoprotein of approximately 160 kD found on the surface of undifferentiated colorectal carcinoma cells; it does not cross-react with other known tumor markers. It is useful for detecting and monitoring colorectal carcinoma.
4892934 PROCESS FOR PREPARING I-IYBRIDOMA CELLS WHICH PRODUCE TUMOR-SPECIFIC MONOCLONAL ANTIBODIES Hajime Yoshida, Nobuo Hanai, Kanagawa, Japan assigned to Kyowa Hakko Kogyo Kabushiki Kaisha High-yielding hybridoma cell lines which secrete monoclonal antibodies capable of binding to tumor cells of one or more types, but not normal cells can be obtained more readily by fusing myeloma ceils with antibody-forming ceils isolated from an animal immunized with tumor antigens, which has previously been made immunological tolerant to normal cell antigens, comprising the total antigens, or at least a proportion of the total antigens, of the normal ceils corresponding to the tumor cells chosen as the source of immunizing antigens,
Monoclonal antibodies being capable of reacting with human squamous cell lung carcinoma, lung adenocarcinoma and large cell lung carcinoma, and non-reactive with human small cell lung carcinoma and normal human lung cells, and recognizing glycoproteins as antigens. Hybridomas having the characteristics of cell line SLC-454 secrete such antibodies. Method of diagnosing human lung cancer and method of therapeutic treatment are described.
4894225 COMBINATION THERAPY USING ANTITUMOR IMMUNOTOXINS WITH TUMOR NECROSIS FACTOR Robert Zimmerman assigned to Cetus Corporation Tumor necrosis factor and a suitable immuotoxin when administered simultaneously or in tandem produce a synergistic effect in treating tumor burden in warm-blooded animals. Methods and protocols for obtaining this syneristic effect are disclosed, as well as compositions effective in this treatment.
4894227 COMPOSITION IMMUNOTOXINS
OF WITH
INTERLEUKIN-2 Paul Stevens, L Houston, Kirston E Koths, Bria Issell assigned to Cetus Corporation Anti-tumor activity in humans can be augmented by administering to the mammalian host a pharmacologically effective amount of mammalian IL-2 and at least one immunotoxin that binds selectively to human tumor cells. The IL-2 and immunotoxin are preferably administered separately to the host. The composition is useful
PATENT ABSTRACTS
have apparent molecular weights of 230K, 215K, 205K, and 190K respectively, with differences in their carbohydrate moieties, nAb 4C is a IgG sub two a, kappa immunoglobulin. 4C has potential use in leukemia, hematopoietic cell differentiation and transplantation diagnoses and therapy.
4892935 ANTI-HUMAN
PULMONARY
CARCINOMA MONOCLONAL ANTIBODY Hajime Yosbida, Nobuo Hanai, Kenya Shitara, Sagamihara, WA, Japan assigned to Kyowa Hakko Kogyo Co Ltd
4892933 MONOCLONAL ANTIBODY FOR COLORECTAL CARCINOMA Ronald Salem, Peter Thomas, Norma Zamcheck, Glenn Steele assigned to New England Deaconess Hospital Corporation; Mallory Institute of Pathology Foundati A monoclonal antibody raised to colorectal carcinoma, and a hybridoma which elicits the antibody, have been produced. This antibody, ND4 has been discovered to react with a new tumor marker, a glycoprotein of approximately 160 kD found on the surface of undifferentiated colorectal carcinoma cells; it does not cross-react with other known tumor markers. It is useful for detecting and monitoring colorectal carcinoma.
4892934 PROCESS FOR PREPARING I-IYBRIDOMA CELLS WHICH PRODUCE TUMOR-SPECIFIC MONOCLONAL ANTIBODIES Hajime Yoshida, Nobuo Hanai, Kanagawa, Japan assigned to Kyowa Hakko Kogyo Kabushiki Kaisha High-yielding hybridoma cell lines which secrete monoclonal antibodies capable of binding to tumor cells of one or more types, but not normal cells can be obtained more readily by fusing myeloma ceils with antibody-forming ceils isolated from an animal immunized with tumor antigens, which has previously been made immunological tolerant to normal cell antigens, comprising the total antigens, or at least a proportion of the total antigens, of the normal ceils corresponding to the tumor cells chosen as the source of immunizing antigens,
Monoclonal antibodies being capable of reacting with human squamous cell lung carcinoma, lung adenocarcinoma and large cell lung carcinoma, and non-reactive with human small cell lung carcinoma and normal human lung cells, and recognizing glycoproteins as antigens. Hybridomas having the characteristics of cell line SLC-454 secrete such antibodies. Method of diagnosing human lung cancer and method of therapeutic treatment are described.
4894225 COMBINATION THERAPY USING ANTITUMOR IMMUNOTOXINS WITH TUMOR NECROSIS FACTOR Robert Zimmerman assigned to Cetus Corporation Tumor necrosis factor and a suitable immuotoxin when administered simultaneously or in tandem produce a synergistic effect in treating tumor burden in warm-blooded animals. Methods and protocols for obtaining this syneristic effect are disclosed, as well as compositions effective in this treatment.
4894227 COMPOSITION IMMUNOTOXINS
OF WITH
INTERLEUKIN-2 Paul Stevens, L Houston, Kirston E Koths, Bria Issell assigned to Cetus Corporation Anti-tumor activity in humans can be augmented by administering to the mammalian host a pharmacologically effective amount of mammalian IL-2 and at least one immunotoxin that binds selectively to human tumor cells. The IL-2 and immunotoxin are preferably administered separately to the host. The composition is useful